These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16882699)

  • 1. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.
    Al-Kuraya K; Novotny H; Bavi P; Siraj AK; Uddin S; Ezzat A; Sanea NA; Al-Dayel F; Al-Mana H; Sheikh SS; Mirlacher M; Tapia C; Simon R; Sauter G; Terracciano L; Tornillo L
    J Clin Pathol; 2007 Jul; 60(7):768-72. PubMed ID: 16882699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of gene amplifications and coamplifications in breast cancer.
    Al-Kuraya K; Schraml P; Torhorst J; Tapia C; Zaharieva B; Novotny H; Spichtin H; Maurer R; Mirlacher M; Köchli O; Zuber M; Dieterich H; Mross F; Wilber K; Simon R; Sauter G
    Cancer Res; 2004 Dec; 64(23):8534-40. PubMed ID: 15574759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR gene copy number increase in vulvar carcinomas is linked with poor clinical outcome.
    Woelber L; Hess S; Bohlken H; Tennstedt P; Eulenburg C; Simon R; Gieseking F; Jaenicke F; Mahner S; Choschzick M
    J Clin Pathol; 2012 Feb; 65(2):133-9. PubMed ID: 22128196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
    Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
    Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
    Varga Z; Moelans CB; Zuerrer-Hardi U; Ramach C; Behnke S; Kristiansen G; Moch H
    Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
    Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predominance of high-grade pathway in breast cancer development of Middle East women.
    Al-Kuraya K; Schraml P; Sheikh S; Amr S; Torhorst J; Tapia C; Novotny H; Spichtin H; Maurer R; Mirlacher M; Simon R; Sauter G
    Mod Pathol; 2005 Jul; 18(7):891-7. PubMed ID: 15803183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
    Tarpgaard LS; Qvortrup C; Nygård SB; Nielsen SL; Andersen DR; Jensen NF; Stenvang J; Detlefsen S; Brünner N; Pfeiffer P
    BMC Cancer; 2016 Feb; 16():91. PubMed ID: 26867764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
    Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
    Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.
    Zaharieva BM; Simon R; Diener PA; Ackermann D; Maurer R; Alund G; Knönagel H; Rist M; Wilber K; Hering F; Schönenberger A; Flury R; Jäger P; Fehr JL; Mihatsch MJ; Gasser T; Sauter G; Toncheva DI
    J Pathol; 2003 Dec; 201(4):603-8. PubMed ID: 14648664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
    Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
    Hagen AI; Bofin AM; Ytterhus B; Maehle LO; Kjellevold KH; Myhre HO; Møller P; Lønning PE
    Acta Oncol; 2007; 46(2):199-203. PubMed ID: 17453369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER-2 and TOP2A coamplification in urinary bladder cancer.
    Simon R; Atefy R; Wagner U; Forster T; Fijan A; Bruderer J; Wilber K; Mihatsch MJ; Gasser T; Sauter G
    Int J Cancer; 2003 Dec; 107(5):764-72. PubMed ID: 14566826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications in head and neck squamous cell carcinoma.
    Freier K; Joos S; Flechtenmacher C; Devens F; Benner A; Bosch FX; Lichter P; Hofele C
    Cancer Res; 2003 Mar; 63(6):1179-82. PubMed ID: 12649172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
    Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
    Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
    Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
    Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
    Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
    Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
    Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.